Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
84 hedge funds and large institutions have $527M invested in Avadel Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 28 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 20
21% more capital invested
Capital invested by funds: $435M → $527M (+$91.6M)
5% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $1.65M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
11% less funds holding
Funds holding: 94 → 84 (-10)
36% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$46.7M |
| 2 |
Bank of New York Mellon
New York
|
+$18.2M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$14.9M |
| 4 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$13.7M |
| 5 |
Millennium Management
New York
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$18.6M |
| 2 |
CM
Castleark Management
Chicago,
Illinois
|
-$10.2M |
| 3 |
D.E. Shaw & Co
New York
|
-$9.24M |
| 4 |
BC
Broadfin Capital
New York
|
-$6.78M |
| 5 |
MACM
March Altus Capital Management
Greenwich,
Connecticut
|
-$6.76M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
101
Sterling Capital Management
Charlotte,
North Carolina
| – | -$308K | -18,000 | Closed |
|
|
TSW
102
Thompson Siegel & Walmsley
Richmond,
Virginia
| – | -$276K | -16,091 | Closed |
|
|
BCM
103
Bienville Capital Management
New York
| – | -$188K | -11,000 | Closed |
|
|
BCM
104
Bourgeon Capital Management
Darien,
Connecticut
| – | -$171K | -10,000 | Closed |
|
|
FAAS
105
First Allied Advisory Services
San Diego,
California
| – | -$171K | -10,000 | Closed |
|
|
CCM
106
Cupps Capital Management
Chicago,
Illinois
| – | -$130K | -7,625 | Closed |
|
|
TRCT
107
Tower Research Capital (TRC)
New York
| – | -$50K | -2,936 | Closed |
|
108
Lazard Asset Management
New York
| – | -$17K | -1,040 | Closed |
|
|
BRWA
109
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$17 | -1,000 | Closed |
|
110
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$9K | -500 | Closed |
|
|
HMS
111
Hanseatic Management Services
Albuquerque,
New Mexico
| – | -$2K | -104 | Closed |
|
|
MFS
112
MSI Financial Services
Springfield,
Massachusetts
| – | +$16 | +1 | New |
|
AVDL Hedge Fund Activity: Q1 2015 in Review
84 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2015, worth a combined $527M — up 21% from $435M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of AVDL and 18 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 33 added.
The largest buyer was Janus Henderson Investors US, opening a new position worth an estimated $46.7M. The largest seller was Deerfield Management, cutting an estimated $18.6M.
- 84 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2015, down from 94 in Q4 2014.
- Funds reported $527M of Avadel Pharmaceuticals stock for Q1 2015, up 21% quarter-over-quarter.
- 18 funds opened new Avadel Pharmaceuticals positions in Q1 2015 and 28 closed out, a net change of -10 holders.
- The largest Avadel Pharmaceuticals buyer in Q1 2015 was Janus Henderson Investors US, an estimated $46.7M added.
- The largest Avadel Pharmaceuticals seller in Q1 2015 was Deerfield Management, an estimated $18.6M sold.
Based on aggregated 13F filings for Q1 2015.